S_ry Factors involved in the control of the biological properties of gliomas, the major form of brain tumour in man, are poorly documented. We investigated the role of transforming growth factor P, (TGF-P,) in the control of proliferation of human glioma cell lnes as well as normal human fetal brain cells. The data presented show that TGF-, exerts a growth-inhibitory action on both human fetal brain cells and three cell lines derived from human glioma of different grades of malignancy. In addition, this growth-inhibitory effect is dose dependent and serum independenL Since TGF-4 is known to be involved in the control of cell migration during ontogenesis and oncogenesis, we investigated the role of this factor in the motile and invasive behaviour that characterises human gliomas in vivo. was Transforming growth factor PI (TGF-i1) is a member of a large family of structurally related proteins which play a role in the control of proliferation, differentiation and morphogenesis in cultured cells and organisms from insects to mammals (reviewed in Massague, 1990 ). TGF-P, was initially defined by its ability to induce anchorage-independent growth of non-transformed rat kidney cells (Roberts et al., 1981 The IPNT-H cell line was derived from a pilocytic astrocytoma of the hypothalamus in a 6-month-old child. Despite the fact that the tumour from which this cell line was derived was histologically classified as a pilocytic astrocytoma, it showed a high proliferative rate in agreement with recent reports demonstrating that occasionally these tumours possess a high mitotic index (Ito et al., 1992). Histological analysis showed the presence of mitoses in one-tenth of high-power fields, but no necrosis or endothelial cell proliferation was noted. In some areas there was an increase in cellularity and very occasional entrapped neurons could be discerned within the tumour. IPNT-H cells were used at passage 7; IPSB-18 was derived from a human grade 3 tumour of the temporal lobe in a 48-year-old man (Knott et al., 1990) Cell proliferation assay Cells were plated at 5 x I04 cells per well in six-well culture plates in DMEM containing FCS in the absence or presence of 5 ng ml-' TGF-,B. The medium was changed once, after 3 days of incubation, and the cell number was determined, after 7 days, by trypinisation and counting in a haemocytometer. All experiments were performed in triplicate and repeated at least twice.
the control of proliferation of human glioma cell lnes as well as normal human fetal brain cells. The data presented show that TGF-, exerts a growth-inhibitory action on both human fetal brain cells and three cell lines derived from human glioma of different grades of malignancy. In addition, this growth-inhibitory effect is dose dependent and serum independenL Since TGF-4 is known to be involved in the control of cell migration during ontogenesis and oncogenesis, we investigated the role of this factor in the motile and invasive behaviour that characterises human gliomas in vivo. TGF-4, was found to elicit a strong stimulation of migration and invasiveness of glioma cells in vitro. In combination with recent data showing an inverse correlation between TGF-Al expression in human gliomas and survival, these findings may suggest that TGF-P, plays an important role in the malignant progression of gliomas in man. A study of the molecular mechanisms involved in the antiproliferative action and the invasion-promoting action of TGF-Al may help to identify new targets in therapy for brain tumours. A combined antiproliferative and anti-invasive therapy could be envisaged.
Gliomas represent the major form of intrinsic brain tumour in man (Russell & Rubinstein, 1989) . The most significant biological feature of these tumours is their local invasive infiltration of normal tissue, irrespective of their histological grade of malignancy. Even low-grade tumours may be poorly demarcated and are hardly ever properly encapsulated; consequently, their complete surgical removal is difficult, if not impossible. Not surprisingly, they frequently recur and therefore carry a poor prognosis. The factors and mechanisms involved in this invasive behaviour as well as in the control of glioma cell proliferation are poorly documented.
Transforming growth factor PI (TGF-i1) is a member of a large family of structurally related proteins which play a role in the control of proliferation, differentiation and morphogenesis in cultured cells and organisms from insects to mammals (reviewed in Massague, 1990) . TGF-P, was initially defined by its ability to induce anchorage-independent growth of non-transformed rat kidney cells (Roberts et al., 1981 Its strong inhibitory action has been demonstrated on various cell types, including both normal and transformed epithelial, endothelial, fibroblast, lymphoid and haematopoietic cells. In addition, TGF-P has been shown to stimulate extracellular matrix formation and thereby modulate cell adhesion and migration (Massague, 1990) . In spite of the considerable number of studies aimed at elucidating the action of TGF-P, in various tissues, little is known about its role in the central nervous system (CNS) . It has been recently demonstrated that TGF-PI exerts an inhibitory effect on the proliferation of normal rat astroglial cells in culture (Labourdette et al., 1990; Lindholm et al., 1992) . It has also been reported that TGF-P, plays a role in the control of differentiation of normal astrocytes in the developing and adult mouse (Sakai et al., 1990) . We have therefore studied the action of TGF-P, on proliferation of neoplastic and normal human glia, cells which represent 50% of the brain's volume and play vital roles in the developing and adult CNS.
We have also investigated the role of TGF-P1 in the characteristic motile and invasive behaviour of human glioma cells since this factor is known to play a central role in the control of cell adhesion and migration during ontogenesis and oncogenesis (Massague, 1990 The IPNT-H cell line was derived from a pilocytic astrocytoma of the hypothalamus in a 6-month-old child. Despite the fact that the tumour from which this cell line was derived was histologically classified as a pilocytic astrocytoma, it showed a high proliferative rate in agreement with recent reports demonstrating that occasionally these tumours possess a high mitotic index (Ito et al., 1992) . Histological analysis showed the presence of mitoses in one-tenth of high-power fields, but no necrosis or endothelial cell proliferation was noted. In some areas there was an increase in cellularity and very occasional entrapped neurons could be discerned within the tumour. IPNT-H cells were used at passage 7; IPSB-18 was derived from a human grade 3 tumour of the temporal lobe in a 48-year-old man (Knott et al., 1990) 18 h at 37C in a humidified 95% air/5% carbon dioxide atmosphere. After incubation, the filters were treated and the cells counted as described above for the motility assay. All the assays were carried out in triplicate, and the assay repeated twice.
The standard deviations were typically less than 10% in individual experiments and thus are not presented.
Results
Growth-inhibitory effect of TGF-P, on glial cells
The effect of TGF-0, on the growth of three human glioma- The human glioblastoma cell line IPRM-5 was inhibited by 40%, while TGF-P, growth-inhibitory effect is serwn independent TGF-B, has also been shown to be growth stimulatory depending on cell type, culture conditions and the presence of other mitogenic factors. For example, Massague (1984) has shown that TGF-P, stimulates proliferation of AKR-2B mouse fibroblasts in 'mitogen-poor' medium. We therefore studied the effect of TGF-P1 on the IPNT-H cell line at different concentrations of serum (Figure ld) . TGF-P1 was seen to exert a growth-inhibitory effect independent of the concentration of FCS present. A 35% growth inhibition was obtained in 20% serum concentration, a 37.5% inhibition in 10%, a 30% inhibition in 5%, a 50% inhibition in 2.5% and a 30% inhibition in 1%. In serum-free medium (0%), the cell number dropped from 8.8 x I0 cells per well to 2 x 104 cells per well.
TGF-P, stimulates glioma cell migration in vitro
One of the most important biological hallmarks of gliomas is their extensive local diffuse spread into the brain. The precise mechanisms involved in this invasive behaviour are not fully understood. Among the well-established biological roles of TGF-P, is its stimulation of extracellular matrix (ECM) formation (Massague, 1990) . This action generally leads to an up-regulation of cell adhesion and may therefore modify the motile behaviour of cells. It was therefore important to study the effect of TGF-P, on glioma cell motility and invasiveness in vitro. Eight-micron-porosity polycarbonate filters, in modified Boyden chambers, were used to assess the effect of TGF-P, on motility. PDGF was used in these studies as a chemoattractant on the basal side of the filter since this factor has already been shown to have a pronounced chemotactic effect on astroglial cells in vitro (Bressler et al., 1985) . The highly malignant, glioblastoma-derived, cell line IPRM-5 did not attach to the filter and was therefore unable to migrate (Figure 2a (Wilcox & Derynck, 1988a,b) .
In addition, TGF-, has a strong inhibitory effect on mouse astrocyte proliferation (Sakai et al., 1990 (Massague, 1990) . (Massague, 1990 (Mazewski et al., 1993) .
It is known that tumorigenesis is accompanied by anaplasia. Moreover, glial cells originate from the neuroepithelium and are characterised by a high migratory potential during their development (Shepherd, 1983 (Basler et al., 1993) which are characterised by a motility similar to that of neuroepithelial cells (Shepherd, 1983) . Interestingly, melanocytes also orginate from the neural crest, and melanomas are characterised by their high migratory, invasive and metastatic potential (Cheresh, 1991) .
It has been previously reported that TGF-P1 is expressed in both low-and high-grade malignant gliomas (DeMartin et al., 1987; Constam et al., 1992; Mazewski et al., 1993) . In addition, these tumours are often accompanied by an inflammatory reaction at the border between the tumour and the normal brain structures (Russell & Rubinstein, 1989) .
The inflammatory cells include B lymphocytes and macrophages, which are known to release TGF-P1 (Sporn & Roberts, 1988) . Therefore, these cells may constitute an additional important source of TGF-P for glioma cells in vivo, with which to arrest the proliferation of glioma cells. However, this action may be detrinental to the normal tissue because it favours its infiltration by tumour cells. This is consistent with the findings of Lindholm et al. (1992) , who suggested that TGF-pl, released from macrophages and microglial cells, strongly inhibits astroglial proliferation and controls scar formation after brain injury.
TGF-P, has been considered as a potential therapeutic factor in many pathological conditions (Sporn & Roberts, 1992) . However our data suggest that such therapeutic applications (particularly in cancer therapy) should take into account its possible role in migration and invasiveness.
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